Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

Eligible patients were randomly assigned 1:1 to receive ribociclib at 400 mg per day via a 3-weeks-on, 1-week-off dosing schedule for 3 years in combination with a nonsteroidal AI for at least 5 years ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...

Researchers appear to have found a solution for breast cancer patients who do not respond well enough to the common treatment ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

The Food and Drug Administration has approved Enoby, a biosimilar to Prolia, and Xtrenbo, a biosimilar to Xgeva.

She emphasized that while elacestrant has properties similar to other agents, imlunestrant is closer to a “pure” ER ...

Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, ...

Inluriyo is approved for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer after prior endocrine therapy failure. The EMBER-3 trial showed Inluriyo reduced cancer progression or death ...